Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application
Ist Teil von
Cancer letters, 2022-10, Vol.546, p.215840-215840, Article 215840
Ort / Verlag
Clare: Elsevier B.V
Erscheinungsjahr
2022
Quelle
ScienceDirect journals Piacenza
Beschreibungen/Notizen
T cell receptor-engineered T (TCR-T) cells targeting neoantigens present potential immunotherapy for solid tumors. With the continuous optimization of the entire production procedures, the manufacturing process of TCR-T cells is becoming more efficient and productive. However, clinical-scale manufacturing of TCR-T cells still encounters tremendous challenges. Here, we summarize the latest progress of neoantigen-targeted TCR-T cell therapy and focus on the technical difficulties in preparing personalized neoantigen-targeted TCR-T cells and the challenges in clinical applications. Possible approaches for improving TCR-T cell therapy are discussed as well in this review.
•Neoantigen-targeted TCR-T cell therapy is one of the most promising immunotherapies for solid tumors.•Neoantigen-targeted TCR-T cell therapy has good safety and efficacy.•The timely and effective identification of neoantigens is still the main obstacle to personalized tumor immunotherapy.•The establishment of a shared neoantigen TCR library shortens the time of neoantigen identification.